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Summary : Pain is an essential subjective warning 
symptom that can transform into a disease when it 
becomes chronic and affects the patients’ quality of 
life. The oxytocinergic system has long been known 
to play a physiological role in pain perception and its 
psychological aspects. Despite potential implications 
for pain treatment, the oxytocinergic system has not yet 
been therapeutically targeted in clinical practice. This 
narrative review explores the latest scientific findings on 
the subject, and discusses some of the unexplored leads 
for the clinical use of oxytocin in the domain of pain 
treatment.
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Central Nervous System. 
The International Association for the Study 
of Pain defines pain as ‘an unpleasant sensory 
and emotional experience associated with actual 
or potential tissue damage, or described in terms 
of such damage’ (1). It is, however, important to 
differentiate acute pain from chronic pain. Acute 
pain acts as a warning sign, while chronic pain is a 
disease. For years, intense effort has been granted 
for the understanding and control of chronic pain, 
leading to therapeutic options that often have 
debatable long-term efficacy.
Recently, a growing interest has emerged for 
oxytocin (OT), a nonapeptide synthesized by 
specific hypothalamus nuclei and secreted by the 
posterior pituitary gland. Although OT is already 
known for its effect on the uterine muscular fibers 
during delivery (2), and for its role in milk-ejection 
during breastfeeding (3), recent studies have shown 
that it could have more properties, including some 
that may be of interest in the domain of algology.
This article aims at reviewing current knowledge 
on the analgesic properties of OT, and discussing 
the potential advantages it may have in clinical pain 
management. The first part briefly describes the main 
physiological mechanisms of pain. The currently 
known properties of OT are then reviewed, at the 
light of the most recent scientific data, and, finally, 
hypotheses regarding eventual clinical interest in 
the treatment of pain are discussed. 
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2. The p hysiop aThology of p ain
2.1 The perception of pain
This review focuses on pain and its perception, 
not on nociception. The latter is a physiological 
process involving the cutaneous, muscular and 
articular nociceptors, as well as the pathways 
transmitting the information they produce to 
the brain. Pain supposes the integration of this 
information by the brain, in a more complex 
framework, adding elements such as emotions, 
stress, or even cultural influence to end up with a 
subjective sensation. 
2.1.1 Nociceptors
The nociceptors are relatively non-specialized 
receptors that can detect potentially damaging 
stimuli and transform them into nerve impulses 
(4). They can be found at any place that is sensitive 
to noxious stimulation. There are three main 
types of nociceptors: the mechanical and thermal 
nociceptors, which both involve Aδ fiber axons, and 
poly-modal nociceptors, which involve C fibers (5). 
2.1.2. Stimulus generation
The exact mechanism involved in the creation 
of nociceptive information is not known with 
precision. It appears that stimulus generation 
depends on numerous mediators secreted locally by 
injured tissues. Other substances like substance P and 
calcitonin gene-related peptide (CGRP) are released 
at the peripheral extremities of neurons emerging 
from the spinal ganglia. All those mediators create 
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playing a role in the emotional side of pain. The last 
ascending tract is the spinomesencephalic tract (9).
2.1.6. Afferent supraspinal terminations
Thalamus is the focal point of somatosensory 
information. It includes two nuclear functional groups: 
the posterior and the lateral one. The latter receives 
information from the spinothalamic tract. Studies have 
shown that inhibitory interactions between the ventral 
posterolateral (VPL) and ventral posteromedial (VPM) 
allow modulating the propagation of pain towards 
the brain (6). The posterior nuclear functional group 
creates connections with the insula and the cingular 
cortex, and takes part in the cognitive and emotional 
aspect of pain (6). 
a ‘peripheral soup’, which activates the nociceptors, 
and induce peripheral sensitization. 
2.1.3 Primary afferent fibers
There are several types of primary afferent 
fibers. They are listed in Table 1 (5) (6) (7).
2.1.4 Posterior horn of the spinal cord 
Nociceptive fibers enter the spinal cord at the 
Lissauer tract, a white matter region that caps the 
dorsal horn. Inside it, the fibers cross the midline 
and go upward to the brain stem. (8). 
Similarly to other places within the nervous system, 
neurons of the spinal cord are grouped in functional 




myelination Axon’s diameter Conduction velocity Function
Aa High Very large: 13 to 20 µm Very fast: 80 to 120 m/s Proprioception.
Ab High Large: 6 to 12 µm Fast: 35 to 70 m/s Epicritic (touch)
Ad Poor Small: 1 to 5 µm Slow: 5 to 30 m/s Primary pain: fast and 
well-localized pain
C None Very small: 0.2 to 1.5 µm Very slow: 0.5 to 2 m/s Secondary pain: higher 
latency, slower and 
badly localized pain
Table 1
Table of the different types of somatosensory afferent fibers.
laminae’. The posterior horn includes lamina I to V 
and the anterior horn the VI to IX. Laminae I and II 
receive information from thin myelinated fibers (Ad) 
and non-myelinated fibers (C). Laminae III and IV 
only receive impulses from thick myelinated fibers 
(Aa and Ab). Laminae V receives information from 
different types of fibers, allowing the management 
of various types of nerve impulses (6).
This organization of the posterior horn into laminae 
is also important for the projection towards the 
brainstem and the thalamus. The nervous pathway 
towards the main thalamic nuclei implicated in pain 
control comes from the laminae II, also known as 
‘substantia gelatinosa of Rolando’ (SGR), which 
receives direct thin-diameter fiber terminations (7).
2.1.5. Ascending spinal tracts
Nociceptive information is carried by the 
anterolateral system, which, contains several distinct 
pathways: the spinothalamic tract, transporting 
information about the localization of pain toward 
the intralaminar and ventral posterior nuclei of 
the thalamus. A third neuron projects either to the 
somatosensory cortex (7) or to the periaqueductal 
gray matter (PAG) (9); and the spinoreticular tract, 
2.2. The modulation of pain
2.2.1. Descending tracts 
Acute and chronic pain is modulated by descending 
tracts emerging from different parts of the brain. Controls 
emerging from the same area can inhibit or facilitate the 
transfer of nociceptive information (10). They project 
onto the dorsal horn of the spinal cord. (11). They can 
be tonic or, more often, modulate the balance between 
inhibition and facilitation. They constitute an efferent 
arm of the effect of behavior, as well as emotional and 
pathological states on pain perception (10). 
The PAG plays a key role in the endogenous control 
of pain. It receives nerve impulses from the frontal and 
insular cortex, the hypothalamus and the amygdala 
(7). The periaqueductal gray, parabrachial nucleus 
and the solitary tractus nucleus communicate with the 
rostral ventromedial medulla which projects directly 
to the dorsal horn of the spinal cord. The involved 
neurotransmission system is noradrenergic and 
serotonergic. The periaqueductal gray and the rostral 
ventromedial medulla contains high concentrations 
of opioid receptors, being one of the effectors of the 
analgesic effect of opioids (9).
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As expected, the main agonist of the receptors is OT; 
however, it shows a weak ligand selectivity profile. 
For instance, arginine vasopressin (AVP) acts as a 
partial agonist. It requires a concentration multiplied 
by 100 in order to elicit the same level of response. 
Moreover, the binding of OT to its receptors is 
modulated by several hormones, notably gonadal 
steroids like testosterone and estrogens. In the brain, 
estrogens exert only a modest influence on the 
synthesis of OT, but they have a pronounced effect 
on the regulation of OTR. These hormones increase 
the affinity of OT toward its receptor. Furthermore, 
it has been shown, in vitro, that OTR expression 
could be raised by activating either the protein 
kinase A (PKA) or protein kinase C (PKC). Like 
most other G protein–coupled receptors (GPCRs), 
the OTR can be active without need of binding 
any agonist. Similarly, OTR may undergo rapid 
homologous desensitization following persistent 
agonist stimulation (13). 
OTR is mainly expressed by myoepithelial cells 
of the mammary glands, the myometrium and the 
endometrium of non-pregnant women. In the central 
nervous system, the expression of the receptors is 
uneven. Study on primate models showed that OTRs 
are localized both on hypothalamic neurons and 
astrocytes. For the regional distribution, however, 
their locations vary depending on the species and 
have yet to be precisely described in humans. This 
expression disparity has raised the question of 
possible subtypes of the receptors. Such subtypes 
have been suggested to explain the evidenced 
differences in pharmacological profiles or immuno-
reactivity patterns. So far, studies failed to issue any 
evidence to the benefit of this theory (13). 
2.2.2. Endogenous opioids
Analgesic medications typically act through 
a modulation of neurotransmission within the 
ascending and descending nociception pathways. 
The endogenous opioid system is an interesting 
target for the development of analgesic medications. 




Oxytocin is a nonapeptide hormone that 
is primarily synthesized by the magnocellular 
and parvocellular neurosecretory cells of the 
paraventricular (PVN) and supraoptic nuclei (SON) 
of the hypothalamus. It is released into the peripheral 
circulation by the posterior pituitary gland. Oxytocin 
acts both as a hormone through its peripheral effects, 
and as a neurotransmitter through its central action 
(7). Table 2 shows two oxytocinergic neurons type.
Magnocellular neurosecretory cells are located in 
the SON and PVN, whereas the parvocellular cells 
are found only in the PVN. Some of them project to 
the forebrain, including the accumbens nucleus and 
the central nucleus of the amygdala, thus exhibiting 
a central action (12).
Parvocellular cells have mainly a peripheral effect 
through their hormonal secretion at the level of the 
posterior pituitary gland. More recently, it has been 
shown that parvocellular-released OT plays a critical 
role in modulating breathing, the cardiovascular 
system, social behavior, and nociception. However, 
the place of the parvocellular and magnocellular 
cells within the oxytocinergic system remains 
unclear (12).
Neurosecretory cell Localization Projection Fonction
Magnocellular Supraoptic and
paraventricular nuclei
Forebrain Released OT into the systemic blood flow 
Parvocellular Paraventricular nucleus Nuclei in the brainstem
and spinal cord
Not yet understood, probably in the
generation of nociveption
Table 2
Known oxytocinergic neurons of the thalamus.
3.2. Oxytocin receptor
The OT receptor (OTR) is a rhodopsin-
type member of the G protein-coupled receptors 
family, characterized by a structure containing 
seven transmembrane helices. It has three potential 
N-glycosylation sites in its extracellular NH2-
terminal domain (13). 
3.3. Peripheral effects of oxytocin
3.3.1. Potential modulation of inflammation 
Oxytocin has also an effect on the inflammatory 
cascade. Oxytocin reduces the production of 
cytokines and NF-kB. (14). It has been demonstrated 
to promote the transduction of the signal coding for 
a protein kinase that is responsible for the positive 
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3.4.1. Animal models
Oxytocin is simultaneously a hormone and a 
neurotransmitter engaged in several physiological 
processes. In animals, both central and peripheral 
OT administration, and the endogenous stimulation 
of the nuclei responsible for the release of OT, 
are responsible for increased pain tolerance and 
decreased perception of acute pain. These effects are 
blocked by the administration of a selective OTR 
antagonist (20). A high tolerance to pain is associated 
with higher OT plasma concentrations (15). 
3.4.2. Central effect of oxytocin
In the central nervous system, and similarly to cortisol 
and estrogen, OT is involved in the coordination of 
behavior and stress response (7). Oxytocin works as 
a neurotransmitter in the hippocampus, amygdala, 
regulation of the cyclo-oxygenase 2 synthesis (15). 
Ongoing research looks at its anti-inflammatory 
properties in other patients than the pregnant 
woman, and in patients with some cardiac and 
bowel diseases (16) (17). 
3.3.2. Other effects 
Oxytocin have effects on lactation (18) (19), 
and on the uterus (18) (3). It also participates 
to wound healing, and in the differentiation of 
cardiomyocytes. These effects are beyond the scope 
of this article (7). 
3.4. Oxytocin effects on pain
Several studies on a potential effect of OT 
administration on pain have already been published. 
They are summarized in Table 3, and commented 
hereafter.
Source Study type Participants Pain evaluation and type of pain Main findings







- Acute thermal pain (cold).
- Pain assessed by visual 
analogue scales and the SF-
MPQ-2.
- Oxytocin administration reduces acute pain 
sensitivity.
- Lower pain unpleasantness, lower pain 
intensity and higher pain threshold.
- Oxytocin administration reduces acute pain 
sensitivity.









- 36 participants 
- Acute thermal pain (heat).
- Pain and pain unpleasantness 
assessed by visual analogue 
scales. 
- Functional magnetic resonance 
imaging to assess changes in the 
whole brain activity as well as 
in the amygdala.
- Modest effect of OT on heat intensity 
ratings.
- Small but significant decline of bilateral 
amygdala activity.
- None effect was proportional to temperature, 
and OT affects the intensity of heat, not its 
unpleasantness. An anti-nociceptive effect 
of OT could not be demonstrated.









- Pain was assessed by the 
movement of the rats after 
stimulation.
- Rats who received placebo were able to 
withstand higher intensities of electric 
shocks on their tail before moving than rats 
having received OTR antagonists intra-
cerebrally.









- Acute thermal pain (heat).
- Pain was assessed by visual 
analogue scales.
- Patients who receive intranasal OT are 
more tolerant to laser-induced finger pain.
- Patients who receive intranasal OT show 
changes in cortical activity.









- 18-50 years old
- 36 participants
- Acute thermal pain (heat) while 
being shown emotional pictures 
(positive, neutral, negative).
- Pain and pain unpleasantness 
were assessed by VASs.
- Functional magnetic resonance 
imaging was performed at the 
same time.
- The positive emotional context decreases 
the perception of pain, while the negative 
emotional context increases it.
- Oxytocin significantly strengthened both 
effects.
- No direct analgesic effect of OT was 
evidenced.








- 80 participants 
(5 excluded for 
technical failure)
- Acute thermal pain (heat) 
after application of a placebo 
ointment on one arm and a 
control on the other one.
- Pain was assessed by visual 
analogue scales.
- Pain was reduced for the arm receiving 
the placebo ointment as compared to the 
control arm in both groups.
- The placebo analgesic response was 
significantly higher in the OT group as 
compared to the saline group, although 
indicators of analgesia were identical for 
both groups.
Table 3
Published studies on pain modulation after oxytocin administration.
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specific neurotransmitter, the arginine vasopressin 
(AVP). Similarly to OT, AVP is synthesized in 
the magnocellular neurosecretory cells of the 
paraventricular and supraoptic nuclei of the 
hypothalamus. Both molecules are sent to the 
posterior lobe of the pituitary gland to be secreted 
into the bloodstream. AVP can also be secreted by 
PVN neurons that project to the periaqueductal gray 
(22).
3.4.3.2. Direct oxytocinergic projection on the 
posterior horn 
The stimulation of the PVN, as well as OT 
administration activates presynaptic receptors 
located superficially in the dorsal horn. This effect in 
turn stimulates GABAergic interneurons. The latter 
are inhibitory neurons that block, at a presynaptic 
level, the nerve impulses from Ad and C fibers to the 
WDR neuron of lamina I and II (20). 
In addition, PVN stimulation reduces the extent of 
WDR neuronal response facilitation by the afferent 
Ad and C fibers. This mechanism could also work at 
the post-synaptic level, by modulating the responses 
of postsynaptic neuronal projections of the posterior 
spinal column to a nociceptive influx (20). 
3.4.3.3. Biopsychosocial model of pain 
The biopsychosocial model of pain is an attempt 
to explain pain in a more accurate way, considering 
non-biological parameters. It was proposed in 
1977 by Engel. In addition to neurophysiological 
elements, this model takes account of behavior 
and its influences. Oxytocin is a key factor in the 
coordination of behavior (20). 
The Impact of Attention
Attention is a cognitive process that enhances 
the perception of useful stimuli, and diminishes 
the perception of non-useful ones. Focusing 
one’s attention on a painful stimulus increases the 
sensation of pain, while focusing on something else 
helps decrease it (7).
The Placebo Effect
The placebo effect is a well-known and yet 
badly understood process affecting all medical 
disciplines. Its impact varies and depends on the 
patient confidence in the information he or she has 
been given, but, more importantly, is affected by the 
trust in the truthfulness of the information. Oxytocin 
being a key factor in the processes of trust, it is not 
surprising that studies have been able to establish 
that intranasal OT administration increases the 
placebo effect (23). 
hypothalamus and nucleus accumbens. In the 
amygdala, the peptide participates in the response to 
threats, stress, anxiety and nociceptive influx. Stress 
and anxiety are known to modulate the perception 
of pain (7). 
The effect of OT on the amygdala provokes an 
inhibition of the hypothalamic-pituitary-adrenal 
axis. This axis controls the production of cortisol, 
referred to as the ‘stress hormone’. The subsequent 
decrease in cortisol reduces the influence of 
anxiety on nociception, although the involved 
pathways are still unclear (7). Noteworthy, there is 
substantial interaction between the regions of the 
Fig. 1. — Central effect of OT.
brain controlling autonomic functions, and those 
responsible for managing nociception (21). Those 
two regions happen to be highly connected (7). 
Figure 1 outlines the central actions of OT. 
3.4.3. Possible biological mechanisms of the 
oxytocin analgesic effect
3.4.3.1. Endogenous opioid system 
In animal models, the OT analgesic effect has 
been linked to its interaction with the endogenous 
opioid system. Indeed, the administration of 
antagonists of the k-opioid and µ-opioid receptors 
partially blocks the OT analgesic effect (20). 
The opioid system, located in the periaqueductal 
gray, activates a series of descending control 
pathways that prevents the spinal transmission of 
pain information. It is thought that OT stimulates 
the release of endogenous opioids. Indeed, the 
administration of the peptide in the periaqueductal 
gray provides anti-nociception, which can then 
be revoked by the administration of an opioid 
antagonist (20).
However, the mechanism of action of OT 
on the opioid system remains unclear. A 
possibility is that this effect is mediated by a 
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4. newesT research and whaT They bring To The 
undersTanding of The role of oT in The p hysiology 
of p ain
A craze for studying the relationship between 
the OT system and analgesia has emerged recently. 
The idea is to find additional pharmacological 
means to control pain, and prevent it from becoming 
chronic. 
4.1. Evolution of the physiological model
4.1.1. Highlighting the existence of an oxytocin 
analgesic activity
Studies increasingly seek to document a link 
between the OT system and analgesia. Up to now, 
the assessment of pain relied on subjective scales 
or on the variation of hormonal levels such as the 
cortisol plasma concentration.
Oxytocin could likely reduce the pain threshold. 
Rats that received a placebo can withstand higher 
intensities of electric shocks on their tail before 
moving than rats having received OTR antagonists 
intra-cerebrally (26).
Patients who receive intranasal OT are more tolerant 
to laser-induced finger pain, which is specifically 
mediated by afferent Ad and C fibers. Furthermore, 
changes in electrophysiological patterns suggesting 
a change in cortical activity can be demonstrated 
in patients who received OT, while no change is 
The Impact of Emotions 
As mentioned above, OT has an anxiolytic 
effect while anxiety plays a role in pain perception 
(24).
The Impact of a Strong Social Support 
Studies have shown that a strong social support 
reduces pain after surgery or labor. This could be 
linked to the effect of OT on contentment, calmness, 
and security (7) (Fig.2). 
 
3.4.4. Potential use of synthetic agonist of oxytocin 
receptor in place of oxytocin
In 2011, De Bonis et al. preformed a prospective 
controlled clinical trial to compare the effectiveness 
of OT and carbetocin, a synthetic agonist of OTR, in 
reducing post-partum hemorrhage after a cesarean 
section in 110 women. The authors decided to 
also take account of the abdominal pain and use 
of analgesic medications after the procedure. 
Their results showed that women treated with car- 
betocin showed a lower level of abdominal pain 
and a decreased use of paracetamol during the post-
operative period. In their publication, the authors 
postulate that this reduction may be due to a lower 
amount of medication received, and hence to dif-
ferent characteristics of the uterine contractions 
with carbetocin. Yet, it cannot be ruled out that a 
synthetic agonist of OTR such as carbetocin is actual- 
ly amplifying the oxytocinergic effect on pain (25). 
Fig. 2. — The effects of oxytocin on pain.
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4.1.3. Discovery of a new population of oxytocin 
neurons
Recently, Eliava et al. have described the 
existence of a new population of approximately 
30 parvocellular neurons in the PVN of the 
hypothalamus in animal models. These cells project 
onto both hypothalamic SON and the deep layers of 
the spinal cord (12). 
Until now, the established ‘dogma’ was an absence 
of communication between the two types of 
oxytocinergic neurons, namely the parvocellular and 
magnocellular neurons. If confirmed, the discovery 
made by Elivia and colleagues would establish that 
a group of neurons connecting both types exists, 
and that these neurons are oxytocinergic (12). 
The axons of this new population seem to extend 
to the deep layers of the spinal cord, and are 
connected with neurons expressing neurokinin 
receptors (NK1R) and OTR. Those are described as 
Wide Dynamic Range (WDR) neurons, which are 
activated by nociceptive influxes. The administration 
of capsaicin on the skin increases c-Fos expression 
in those neurons, a marker of neuronal activity. The 
release of OT by this new population of neurons 
would inhibit the WDR neurons, and therefore the 
downstream transmission of the nociceptive influx 
(12). 
Consequently, OT modulates the nociceptive influx 
through two routes. One way is direct, fast, and 
allows the inhibition of WDR neurons in the spinal 
cord. The second is indirect, slower, and provokes 
the release of OT by SON neurons in the blood 
stream (12). The inhibition of the newly described 
population has no impact on the transmission of 
thermal and mechanical information (12). 
Interestingly, the newly described population is 
a very restricted one, counting only about thirty 
neurons. In animal models, its activation modulates 
the inflammatory pain only, and has no impact on 
neuropathic pain. Such properties could be used in 
the development of future analgesic medications 
(12). 
4.2. Evolution of the biopsychosial model
4.2.1 Oxytocin-related modulation of pain in 
relation with emotional changes
Intra-nasal OT administration modifies the 
impact of the emotional background on pain. In 
a randomized double-blind placebo-controlled 
crossover study, subjects were given intranasal OT 
or placebo. Thereafter, they underwent functional 
magnetic resonance imaging while being shown 
detected in placebo-treated patients. These results 
suggest that OT modulates the neural processes 
responsible for painful perception (27).
In another study, Rash et al. designed a placebo-
controlled, double-blind, within-participant 
crossover investigation studying the effect of 
synthetic intranasal OT on acute pain sensitivity. 
Forty healthy participants, male and female, were 
asked to immerge one of their hands into cold 2C° 
water and to evaluate the threshold and intensity of 
the pain, as well as the unpleasantness. The patients 
were also asked to complete the “Short-form McGill 
Pain Questionnaire 2” which assesses neuropathic 
and non-neuropathic pain. One group was given 
40 UI of intranasal OT, while the other was given 
placebo (28). The results showed a decrease in 
pain intensity and pain unpleasantness, an increase 
in pain threshold for the OT group, as compared 
to the placebo group. The pain as assessed by the 
Short-Form McGill Pain Questionnaire-2 was also 
significantly lower (28), but the difference between 
the two groups was small. Of note, this study has a 
few limitations that do not permit a generalized use 
to a wider population.
It is also worth noting that the main effect of 
intranasal OT in the Rash et al. study was on the 
descriptors of the neuropathic subscale of the Short-
Form McGill Pain Questionnaire-2 (28).
Zunhammer et al. investigated how intranasal 
OT effects pain perception using a randomized, 
placebo-controlled, double-blind, crossover trial. 
With the help of 36 healthy male volunteers aged 18 
to 50 years, the team determined a thermal threshold 
of each participant 40 minutes after they self-
administered an intranasal spray containing either 
OT or placebo. Thereafter, a 14 successive seconds 
thermal stimulation was applied while participants 
were undergoing functional magnetic resonance 
imaging. After each stimulation, the participants 
were asked to rate pain and unpleasantness using 
visual analogue scales. Functional magnetic 
resonance imaging analysis was set to assess 
changes in whole brain activity, as well as in the 
amygdala (29). This trial showed a compelling 
although modest effect of OT on heat intensity 
ratings (p = 0.046). This action was linked with a 
small but significant decline in bilateral amygdala 
activity. It was not possible to prove any effect of 
OT on the rest of the brain, and it is worth noting 
that neither effect was proportional to temperature, 
leading the authors to the conclusion that an anti-
nociceptive effect of OT could not be demonstrated. 
Indeed, OT affected the intensity of perceived heat, 
not its unpleasantness (29) 
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Beyond its role in pain perception, the placebo 
effect also affects the response to stress, changes 
autonomic and endocrine functions, and mood or 
cognitive processes (32). Oxytocin increases the 
placebo effect on pain perception through a different 
mechanism than the one involved in its analgesic 
effect. In addition to decreasing the nociceptive 
influx of information, OT decreases its cognitive 
perception (33). Though, the involved mechanisms 
are still poorly understood. An attractive hypothesis 
is that OT favors the trust effect (33). 
Further research is warranted in this field, the main 
difficulty being to design studies that respect ethics, 
and that lead to conclusions being usable in clinical 
practice.
5. conclusion 
Even though pain is a frequent and feared 
symptom, many dark areas remain in the 
understanding of its physiology. The major impact 
of pain on patients’ quality of life, particularly in 
chronic pain, oncological pain, or more complex 
pain syndromes like fibromyalgia, justifies 
continued research on new pharmacological tools to 
reinforce the current therapeutic arsenal.
Among novel therapeutic roads, OT is a promising 
one since several studies have evidenced its 
significant analgesic effect. However, despite 
scientific infatuation and growing number of 
published studies, no consensus on the exact 
mechanism of OT has been reached yet. Its mode of 
action is more than probably multimodal. 
Among the action of OT on pain, inhibition of the 
nerve impulse is the most studied. We know that 
OT-producing neurons in the hypothalamus have 
projections in several areas of the central nervous 
system. They have an inhibitory action on the 
spinal cord, act on distinct part of the forebrain and 
even release neuro-hypophyseal OT as a hormone 
in the peripheral blood stream. OT is as much a 
neurotransmitter as a hormone. OT modulates the 
cognitive perception of pain and modulates the 
cortisol plasma level. It also influences trust, and 
the placebo effect. 
Unfortunately, one of the obstacles on the road to 
a clinical use of OT is its peptide nature. A peptide 
oral intake exposes the peptide to digestion, and 
absence of absorption, and thus loss of function by 
denaturation. The intranasal administration could 
be a solution. However, this brings new concern 
such as the control of the given amount, and would 
still generate difficulties in passing through the 
blood-brain barrier. It might be wise to consider 
several pictures from the International Affective 
Picture System (IAPS). The IAPS is a set of 
standardized, normative emotional stimuli for 
experimental investigations. Each group was 
submitted to heat stimuli (non-noxious, 44.7°C and 
noxious, 47.1°C) and emotional pictures viewing 
(positive, neutral, negative). Baseline temperature 
(35.0°C) and scrambled picture conditions were 
assessed as additional control conditions.
After a 3 to 6 seconds of rest, the participants 
were asked to evaluate the perceived ‘intensity’ 
and ‘unpleasantness’ on two consecutive visual 
analogue scales, with the following endpoints: ‘no 
stimulus perceived’/‘not unpleasant’ and ‘maximally 
intense’/‘maximally unpleasant’, respectively. The 
control group and OT group were then inverted 
after a washout period of at least 7 days to minimize 
the risk of carry-over effects. 
The results of this study show that, for both 
medication conditions, the positive emotional 
context decreases the perception of pain, while 
the negative emotional context increases it. 
However, in both case, OT significantly strengthens 
those effects. Unfortunately, no between-group 
connectivity differences were objectified by 
functional neuroimaging, and no direct analgesic 
effect of OT was shown. The authors suggest this 
may be because noxious stimuli were assessed after 
performing functional imaging, thus after a longer 
interval than in other studies (30).
4.2.2 Placebo effect on pain: action of oxytocin
The placebo response is best depicted as a 
complex psycho-neurobiological process. It hinges 
on several central and peripheral physiological 
mechanisms modulating pain perception, clinical 
symptoms, and largely modifies the response to 
active analgesic medications (31). 
Receiving a placebo activates several brain areas, 
including the anterior rostral cingulate, the dorsal 
lateral prefrontal cortex, the orbital frontal cortex, 
the insula, the nucleus accumbens, the tonsils, the 
medial thalamus, and the periaqueductal gray matter. 
This occurs through a change in dopaminergic and 
opioid neurotransmission. These processes are less 
active in patients suffering from chronic pain (31). 
It has been shown that the implementation of 
emotional and cognitive processes during the 
administration of an otherwise inactive product 
is able, through its placebo effect, to modulate 
several physiological processes, although with large 
inter-individual variability. Factors influencing 
this variability are of genetic, anatomical and 
neuropsychological nature (32). 
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a specific galenic formulation. Such a compound 
could be useful for research as well as clinical use in 
humans. Such research exists, notably in the context 
of oncological diseases. Currently, it seems that the 
solution might come from the use of nanoparticles 
or nanogel, liposome vehicles, intra-thecal injection 
through the cribriform plate, delivery by a modified 
cellular agent or a modification of the target 
molecule (34). Obviously intravenous infusion 
and intramuscular injection are always an option. 
However, this mode of administration brings many 
disadvantages and constraints to patients. It also 
makes their use as chronic treatments impractical. 
All those advances in the understanding of the 
multimodal action of OT offer new therapeutic 
possibilities. One could also reside in the modulation 
of the activity of the newly discovered population of 
oxytocinergic neurons. This might allow promoting 
the inhibitory effect of OT on inflammatory pain. 
Oxytocin could also be used to potentiate the 
analgesic medications already in use by the patient, 
to increase or maintain their efficacy while using 
lower doses. 
Finally, one of the remaining essential objectives 
of future research is to define the target population 
who would benefit from oxytocin treatment. In this 
respect, several points are to be kept in mind. First, 
it is clear that OT will not be effective at relieving 
all types of pain. It would therefore be helpful to 
investigate its efficacy in treating neuropathic, 
inflammatory, and other types of pain separately. 
Second, the vast majority of already published 
studies were performed in healthy volunteers being 
exposed to acute pain. Chronic pain has been poorly 
studied in that respect so far. Third, the effect of 
OT is altered by the emotional context and the 
mood of participants, and by seemingly intrinsic 
characteristics of patients such as a pro-social or 
selfish behavior. It would be beneficial to include 
such variables in forthcoming trials. For example, it 
would be interesting to assess the role of OT in the 
perception of pain in anxious or depressed subjects, 
insofar as those features are common in patients 
suffering from chronic pain. 
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